ESMO Breast Cancer 2019: Industry Sponsored Satellite Symposia

Click on the links below to access the Industry Sponsored Satellite Symposia Invitations.

Thursday 2 May 2019

Innovation in HR+, HER2–Advanced Breast Cancer and the Emerging Role of Biomarkers

Innovation in HR+, HER2–Advanced BreastCancer and the Emerging Role of Biomarkers Thumb

Novartis Satellite Symposium
Thursday 12:00 - 13:00
Berlin Hall
View the satellite invitation

Scientific Exchange Symposium: Estrogen Receptor Positive (ER+) Advanced Breast Cancer – What are the Therapeutic Approaches of the Future?

Estrogen Receptor Positive (ER+) Advanced Breast Cancer – What are the Therapeutic Approaches of the Future? Thumb

Eisai Satellite Symposium
Thursday 12:00 - 13:00
Viena Hall
View the satellite invitation

New Views on HER2-Positive Breast Cancer Low HER2, HER3 and Resistance

New Views on HER2-Positive Breast Cancer Low HER2, HER3 and Resistance Thumb

Medscape Satellite Symposium
Thursday 18:30 - 19:30
Berlin Hall
View the satellite invitation

Hitting Breast Cancer where it Hurts

Hitting Breast Cancer where it Hurts Thumb

Astrazeneca Satellite Symposium
Thursday 18:30 - 19:30
Vienna Hall
View the satellite invitation

Friday 3 May 2019

Advances in Triple-Negative Breast Cancer Care: Exciting Prospects in Personalised Cancer Immunotherapy

Advances in Triple-Negative Breast Cancer Care: Exciting Prospects in Personalised Cancer Immunotherapy Thumb

Roche Satellite Symposium
Friday 13:00 - 14:00
Berlin Hall
View the satellite invitation

Targeting HER Driven Breast Cancer Emerging and Future Options

Targeting HER Driven Breast Cancer Emerging and Future Options Thumb

Daiichi-Sankyo Satellite Symposium
Friday 13:00 - 14:00
Vienna Hall
View the satellite invitation

Changing the Trajectory of HR+/HER2- mBC: From Evidence to Clinical Practice

Changing the Trajectory of HR+/HER2- mBC: From Evidence to Clinical Practice Thumb

Pfizer Satellite Symposium
Friday 13:00 - 14:00
Riga Hall
View the satellite invitation

Addressing Ongoing Clinical Challenges: How Do We Optimize Patient Outcomes with CDK4/6 Inhibition In HR+/HER2- Breast Cancer?

Addressing Ongoing Clinical Challenges: How Do We Optimize Patient Outcomes with CDK4/6 Inhibition In HR+/HER2- Breast Cancer? Thumb

TouchIME Satellite Symposium
Friday 18:30 - 19:30
Berlin Hall
View the satellite invitation

Her Problem is Our Mission

Her Problem is Our Mission Thumb

Mylan Satellite Symposium
Friday 18:30 - 19:30
Vienna Hall
View the satellite invitation

Please note: The European Society for Medical Oncology (ESMO) does not endorse any of the companies, or their products/services, that have sponsored these links.